Cargando…
Role of ubenimex as an anticancer drug and its synergistic effect with Akt inhibitor in human A375 and A2058 cells
BACKGROUND: Malignant melanoma (MM) is a malignant tumor produced by changes in melanocytes in the skin or other organs. In the classification of skin tumor mortality, skin melanoma ranks the highest. Ubenimex, an Aminopeptidase N (APN) inhibitor, is now widely used for cancer as an adjunct therapy,...
Autores principales: | Wang, Xiaoqing, Liu, Yang, Wu, Rongde, Guo, Feng, Zhang, Lijuan, Cui, Mingyu, Wu, Xiangyu, Zhang, Yongfei, Liu, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826084/ https://www.ncbi.nlm.nih.gov/pubmed/29503569 http://dx.doi.org/10.2147/OTT.S157480 |
Ejemplares similares
-
Ubenimex, an APN inhibitor, could serve as an anti-tumor drug in RT112 and 5637 cells by operating in an Akt-associated manner
por: Wang, Xiaoqing, et al.
Publicado: (2018) -
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma
por: YAMASHITA, MASAFUMI, et al.
Publicado: (2016) -
Ubenimex enhances Brd4 inhibition by suppressing HEXIM1 autophagic degradation and suppressing the Akt pathway in glioma cells
por: Han, Liping, et al.
Publicado: (2017) -
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism
por: Liu, Shuai, et al.
Publicado: (2016) -
The Synergistic Activity of Bortezomib and TIC10 against A2058 Melanoma Cells
por: Takács, Angéla, et al.
Publicado: (2021)